search
Back to results

Dietary Nitrate, Vascular Function and Inflammation

Primary Purpose

Hypertension, Inflammation

Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
High-nitrate intervention
Low-nitrate intervention
Sponsored by
University of Vienna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring dietary nitrate, inorganic nitrate-nitrite-nitric oxide pathway, oral microbiome, chronic low-grade inflammation, vascular integrity, high blood pressure, cardiovascular health

Eligibility Criteria

55 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ambulant male and females between 55 and 75 years of age, inclusive
  • Resting systolic blood pressure between 130 and 170 mmHg, inclusive
  • Written informed consent

Exclusion Criteria:

  • Diastolic blood pressure >110 mmHg
  • Type 1 or 2 diabetes mellitus or fasting glucose >7.0 mmol/L
  • Any evidence of acute or chronic disease such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) <50 ml/min)), or cancer which is not in remission
  • Consumption of ≥5 serves of vegetables per day
  • Consumption of a diet estimated to contain >200 mg/d of nitrate
  • Being vegan or vegetarian
  • BMI ≥35 kg/m2 or <18.5 kg/m2
  • Use of nitric oxide donors, organic nitrites/nitrates, sildenafil and related drugs, anti-coagulation, non-steroidal anti-inflammatory or statin-related drugs
  • Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouth wash for a period of 4 weeks before randomisation will be included)
  • Use of antibiotics (within previous 2 months)
  • A change in drug therapy likely to influence blood pressure or major secondary outcomes within the previous month, or the likelihood that drug therapy would change during the study
  • Current or recent (within previous 3 months) engagement in regular structured exercise training (more than 2 hours of moderate to more intense exercise per week)
  • Current or recent (within previous 6 months) loss or gain of >6% of body weight
  • Current or recent (<12 months) regular smoking of >5 cigarettes/day
  • Alcohol intake >140 g per week for women or >210 g per week for men and/or binge drinking behaviour
  • Inability or unwillingness to follow the study protocol
  • Pregnancy or lactation

Sites / Locations

  • Medical University of Vienna
  • University of Vienna

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

High-nitrate (HI-NI) intervention

Low-nitrate (LO-NI) intervention

Arm Description

The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.

The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.

Outcomes

Primary Outcome Measures

Change in forearm blood flow (FBF) response to acetylcholine
Vascular function
Change in forearm blood flow (FBF) response to acetylcholine
Vascular function
Change in 24 hour-ambulatory systolic blood pressure
Blood pressure
Change in 24 hour-ambulatory systolic blood pressure
Blood pressure

Secondary Outcome Measures

Change in granulocyte CD11b expression
Vascular inflammation biomarker
Change in granulocyte CD11b expression
Vascular inflammation biomarker
Change in forearm blood flow (FBF) response to glyceryltrinitrate
Vascular function
Change in forearm blood flow (FBF) response to glyceryltrinitrate
Vascular function

Full Information

First Posted
September 29, 2020
Last Updated
May 9, 2023
Sponsor
University of Vienna
Collaborators
Medical University of Vienna, Queensland University of Technology, Flinders University, Edith Cowan University
search

1. Study Identification

Unique Protocol Identification Number
NCT04584372
Brief Title
Dietary Nitrate, Vascular Function and Inflammation
Official Title
Effects of Dietary Nitrate on Vascular Function, Blood Pressure, the Oral Microbiome, and Biomarkers of Systemic Inflammation in Hypertensive Older Adults: a Randomized, Placebo-controlled Crossover Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
March 28, 2023 (Actual)
Study Completion Date
March 28, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vienna
Collaborators
Medical University of Vienna, Queensland University of Technology, Flinders University, Edith Cowan University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The risk for cardiovascular diseases (CVD) increases with advancing age. Developing effective lifestyle-based strategies to promote, preserve or restore cardiovascular health with aging is a high priority. The overall aim of this clinical research is to investigate the innovative concept that an increased intake of dietary nitrate (through beetroot juice) could be a feasible adjuvant therapy to treat elevated blood pressure and improve blood vessel function in older adults. Inorganic dietary nitrate, found in beetroot and green leafy vegetables, is a source of nitric oxide (NO), a signaling molecule that is important for cardiovascular health. NO is also produced in the human body, but the body's production and availability of NO decrease during ageing and CVD. The declined NO availability is associated with impaired blood vessel function, unresolved inflammatory responses, and an increased CVD risk. Dietary nitrate is an additional NO source. Following the intake of nitrate, NO is produced in a pathway that involves commensal bacteria in the mouth. So far, little is known about whether dietary nitrate improves cardiovascular health in older populations with high blood pressure. The aim of this randomized, placebo-controlled crossover study is to investigate whether the daily intake of nitrate-rich beetroot juice over four weeks translates into improved cardiovascular health-related outcomes in older adults with treated mild high blood pressure. Men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 high blood pressure and who are taking two or more blood-pressure lowering medications will be recruited. The study will investigate whether the increased dietary nitrate intake further lowers blood pressure and improves blood vessel function. A specific aim is to examine whether the nitrate intake results in favorable changes in the oral bacteria community and the systemic inflammatory status, and whether these changes correlate with cardiovascular-related outcomes. This research will offer information on the value of dietary nitrate to counteract chronic inflammation, the latter of which plays a role in developing or worsening cardiovascular disorders, such as high blood pressure. The expected results of this study will provide important new evidence of whether nitrate-rich beetroot juice could be a key component of therapeutic interventions to improve cardiovascular health in individuals with high blood pressure.
Detailed Description
This clinical research is funded by the Austrian Science Fund (FWF, project number: KLI 858). It is based on close collaborations between the University of Vienna and the Medical University of Vienna, with the Department of Clinical Pharmacology at the Medical University of Vienna as the clinical trial center and Prof. M.D. Michael Wolzt as the trial center's coordinating physician. The sponsor is the University of Vienna, as represented by the Principal Investigator Dr. Oliver Neubauer (Research Platform Active Ageing). International collaborations include Dr. Catherine Bondonno, Prof. Hodgson (both Edith Cowan University) Dr. Jonathan Peake (Queensland University of Technology), and Prof. Richard Woodman (Flinders University) (all Australia). Wider research context / theoretical framework: Aging is a major risk factor for cardiovascular disease (CVD). Developing effective strategies to improve cardiovascular health with ageing is a high priority. Emerging data indicate that inorganic dietary nitrate, found in green leafy vegetables and beetroot juice (BRJ), is important for cardiovascular health (Blekkenhorst et al. 2018). These data suggest that small increases in nitrate intake among those with elevated risk for CVD would have a substantial impact, by improving the bioavailability of nitric oxide (NO) through the enterosalivary nitrate- nitrite-NO pathway (involving the oral microbiome). Results from the study group's research suggest beneficial short-term effects of nitrate-rich BRJ on blood pressure and vascular inflammation markers in healthy older adults (Raubenheimer et al. 2017). Hypotheses / research questions / objectives: The proposed clinical study is aimed to examine whether the daily consumption of 2×70 mL BRJ over 4 weeks translates into improved clinical outcomes in older adults with treated grade 1 hypertension. The primary hypothesis is that the increased dietary nitrate intake lowers blood pressure and improves vascular function. The secondary hypotheses are that the increased dietary nitrate intake results in changes in the oral microbiome, favorably modulates the systemic inflammatory status, and that these changes correlate with cardiovascular-related outcomes. Approach / methods: This randomized, placebo-controlled crossover study will involve two 4-week treatment periods, consisting of interventions with nitrate-rich BRJ and nitrate-depleted BRJ, separated by a 4-week washout period. Thirty-five men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 hypertension will be recruited. Twenty-nine participants will be required to complete the study, based on power/sample size calculations with the forearm blood flow (FBF) response to acetylcholine and 24 h-ambulatory systolic blood pressure as the primary endpoints. Principal secondary endpoints are the number of CD11b-expressing blood granulocytes and the FBF response to glyceryltrinitrate. Among various additional secondary and exploratory endpoints, plasma nitrate and nitrite and a broad range of inflammation biomarkers will be measured. Furthermore, the oral microbiome will be analyzed. Level of originality / innovation: Beneficial effects of nitrate have predominantly been observed in healthy populations, but evidence of cardiovascular benefits and anti-inflammatory effects in clinical populations is limited (Raubenheimer et al. 2019). This study addresses the need to determine the efficacy of dietary nitrate to improve cardiovascular health and counteract chronic low-grade inflammation in humans at risk of CVD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Inflammation
Keywords
dietary nitrate, inorganic nitrate-nitrite-nitric oxide pathway, oral microbiome, chronic low-grade inflammation, vascular integrity, high blood pressure, cardiovascular health

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Prospective, mono-center, randomized, double-blind, placebo-controlled, crossover study The study will involve a randomized, placebo-controlled crossover design, with two 4-week treatment periods separated by a 4-week washout period. The two treatments will consist of a 4-week high-nitrate (HI-NI) and a 4-week low-nitrate (LO-NI, i.e., placebo) intervention in older adults with treated grade 1 hypertension, on the background of a low-nitrate diet and unaltered lifestyle.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
The two treatment arm will consist of a 4-week high-nitrate (HI-NI) intervention (using nitrate-rich beetroot juice) and a 4-week low-nitrate (LO-NI) intervention using nitrate-depleted beetroot juice as the placebo. All products will be obtained from the same supplier (James White Drinks Ltd., UK). The nitrate-depleted beetroot juice is generated for research purposes only. The two juices will be indistinguishable by taste, color, smell and packaging. The investigators involved in the data acquisition and analysis will be blind to the trial allocation until the study has been completed and all analyses have been performed.
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High-nitrate (HI-NI) intervention
Arm Type
Active Comparator
Arm Description
The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
Arm Title
Low-nitrate (LO-NI) intervention
Arm Type
Placebo Comparator
Arm Description
The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
High-nitrate intervention
Other Intervention Name(s)
HI-NI
Intervention Description
The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
Intervention Type
Dietary Supplement
Intervention Name(s)
Low-nitrate intervention
Other Intervention Name(s)
LO-NI
Intervention Description
The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
Primary Outcome Measure Information:
Title
Change in forearm blood flow (FBF) response to acetylcholine
Description
Vascular function
Time Frame
Change from baseline FBF at 4 weeks of the HI-NI intervention
Title
Change in forearm blood flow (FBF) response to acetylcholine
Description
Vascular function
Time Frame
Change from baseline FBF at 4 weeks of the LO-NI intervention
Title
Change in 24 hour-ambulatory systolic blood pressure
Description
Blood pressure
Time Frame
Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the HI-NI intervention
Title
Change in 24 hour-ambulatory systolic blood pressure
Description
Blood pressure
Time Frame
Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the LO-NI intervention
Secondary Outcome Measure Information:
Title
Change in granulocyte CD11b expression
Description
Vascular inflammation biomarker
Time Frame
Change from baseline granulocyte CD11b expression at 4 weeks of the HI-NI intervention
Title
Change in granulocyte CD11b expression
Description
Vascular inflammation biomarker
Time Frame
Change from baseline granulocyte CD11b expression at 4 weeks of the LO-NI intervention
Title
Change in forearm blood flow (FBF) response to glyceryltrinitrate
Description
Vascular function
Time Frame
Change from baseline FBF at 4 weeks of the HI-NI intervention
Title
Change in forearm blood flow (FBF) response to glyceryltrinitrate
Description
Vascular function
Time Frame
Change from baseline FBF at 4 weeks of the LO-NI intervention
Other Pre-specified Outcome Measures:
Title
Change in clinical blood pressure
Description
Blood pressure
Time Frame
Change from baseline clinical blood pressure at 4 weeks of the HI-NI intervention
Title
Change in clinical blood pressure
Description
Blood pressure
Time Frame
Change from baseline clinical blood pressure at 4 weeks of the LO-NI intervention
Title
Change in plasma nitrate and nitrite
Description
Marker for nitrate bioavailability and functioning of the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway
Time Frame
Change from baseline plasma nitrate and nitrite at 4 weeks of the HI-NI intervention
Title
Change in plasma nitrate and nitrite
Description
Marker for nitrate bioavailability and functioning of the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway
Time Frame
Change from baseline plasma nitrate and nitrite at 4 weeks of the LO-NI intervention
Title
Change in blood monocyte-platelet aggregation
Description
Vascular inflammation biomarker
Time Frame
Change from baseline blood monocyte-platelet aggregation at 4 weeks of the HI-NI intervention
Title
Change in blood monocyte-platelet aggregation
Description
Vascular inflammation biomarker
Time Frame
Change from baseline blood monocyte-platelet aggregation at 4 weeks of the LO-NI intervention
Title
Change in high-sensitive plasma C-reactive protein (hsCRP)
Description
Inflammation biomarker
Time Frame
Change from baseline plasma hsCRP at 4 weeks of the HI-NI intervention
Title
Change in high-sensitive plasma C-reactive protein (hsCRP)
Description
Inflammation biomarker
Time Frame
Change from baseline plasma hsCRP at 4 weeks of the LO-NI intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ambulant male and females between 55 and 75 years of age, inclusive Resting systolic blood pressure between 130 and 170 mmHg, inclusive Written informed consent Exclusion Criteria: Diastolic blood pressure >110 mmHg Type 1 or 2 diabetes mellitus or fasting glucose >7.0 mmol/L Any evidence of acute or chronic disease such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) <50 ml/min)), or cancer which is not in remission Consumption of ≥5 serves of vegetables per day Consumption of a diet estimated to contain >200 mg/d of nitrate Being vegan or vegetarian BMI ≥35 kg/m2 or <18.5 kg/m2 Use of nitric oxide donors, organic nitrites/nitrates, sildenafil and related drugs, anti-coagulation, non-steroidal anti-inflammatory or statin-related drugs Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouth wash for a period of 4 weeks before randomisation will be included) Use of antibiotics (within previous 2 months) A change in drug therapy likely to influence blood pressure or major secondary outcomes within the previous month, or the likelihood that drug therapy would change during the study Current or recent (within previous 3 months) engagement in regular structured exercise training (more than 2 hours of moderate to more intense exercise per week) Current or recent (within previous 6 months) loss or gain of >6% of body weight Current or recent (<12 months) regular smoking of >5 cigarettes/day Alcohol intake >140 g per week for women or >210 g per week for men and/or binge drinking behaviour Inability or unwillingness to follow the study protocol Pregnancy or lactation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oliver Neubauer, Dr PhD, PD
Organizational Affiliation
University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
For long-time preservation and sharing of the research data, it is planned to use the PHAIDRA digital repository of the University of Vienna (https://phaidra.univie.ac.at). This repository enables the permanent secure storage of digital assists including open access publications and research data necessary to reproduce and to verify the results of the publications. For all publications and other data related to this research that will be made available, all of the individual participant data collected during the trial will be de-identified.
IPD Sharing Time Frame
The plan is to publish the findings in scientific journals and to present them at scientific meetings and to the public after the study is completed.
IPD Sharing Access Criteria
Supporting the Open Access Policy of the University of Vienna, the PHAIDRA repository enables public access of the research data necessary to reproduce and to verify the results of publications from this research.
Citations:
PubMed Identifier
29165355
Citation
Raubenheimer K, Hickey D, Leveritt M, Fassett R, Ortiz de Zevallos Munoz J, Allen JD, Briskey D, Parker TJ, Kerr G, Peake JM, Pecheniuk NM, Neubauer O. Acute Effects of Nitrate-Rich Beetroot Juice on Blood Pressure, Hemostasis and Vascular Inflammation Markers in Healthy Older Adults: A Randomized, Placebo-Controlled Crossover Study. Nutrients. 2017 Nov 22;9(11):1270. doi: 10.3390/nu9111270.
Results Reference
background
PubMed Identifier
31150091
Citation
Raubenheimer K, Bondonno C, Blekkenhorst L, Wagner KH, Peake JM, Neubauer O. Effects of dietary nitrate on inflammation and immune function, and implications for cardiovascular health. Nutr Rev. 2019 May 30:nuz025. doi: 10.1093/nutrit/nuz025. Online ahead of print.
Results Reference
background
PubMed Identifier
29635489
Citation
Blekkenhorst LC, Bondonno NP, Liu AH, Ward NC, Prince RL, Lewis JR, Devine A, Croft KD, Hodgson JM, Bondonno CP. Nitrate, the oral microbiome, and cardiovascular health: a systematic literature review of human and animal studies. Am J Clin Nutr. 2018 Apr 1;107(4):504-522. doi: 10.1093/ajcn/nqx046.
Results Reference
background

Learn more about this trial

Dietary Nitrate, Vascular Function and Inflammation

We'll reach out to this number within 24 hrs